Navigation Links
Applied Integrin Sciences, Inc. Announces Exceptional Results In Ovarian Cancer Study
Date:9/20/2013

NEW YORK, Sept. 20, 2013 /PRNewswire-iReach/ -- Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen.  Funded by the National Cancer Institute through the company's first NCI grant awarded December last year, its lead candidate drug Vicrostatin was combined with a drug-eluting gel and applied into the peritoneum for sustained release of the drug directly to ovarian cancer metastatic tumors. 

"The results our scientists achieved are exceptional", said Thomas C. Chen, MD, Ph.D., the company's Chief Medical Officer, "and suggest an equivalent human treatment for ovarian cancer patients is feasible.  The implications for this treatment are equally compelling as 75% of women first diagnosed with ovarian cancer have stage III or stage IV metastatic disease and 80% of those women fail to survive longer than 20 months post diagnosis.  This approach is early but if we are able to achieve comparable results in human clinical trials with women suffering from ovarian cancer this treatment could considerably change the current standard of care."

The company's two drug candidates previously demonstrated substantial reduced tumor growth and progression in pre-clinical testing against six aggressive cancers: triple negative breast cancer; primary prostate cancer; prostate bone metastasis; ovarian cancer; melanoma; and glioblastoma.  Both drug candidates, Vicrostatin and ADM-01, are recombinant proteins discovered by the company's founding scientists at the University of Southern California's Keck School of Medicine and Norris Comprehensive Cancer Center.  Each uniquely targets specific cell surface receptors that are activated only in actively growing cancer cells and when metastatic cells and cells producing new tumor vasculature are actively motile.  These cancer growth and progression processes are necessary for cancers to seed new metastatic tumors throughout the body and to produce the blood vasculature that is required for tumors to grow and cause death. 

The cancer fighting mechanisms of the company's two drug candidates are very unique and suggest better efficacy, improved safety, and longer sustained therapeutic effects than current cancer drugs.  The company plans to complete pre-clinical development of its lead candidate and file an Investigational New Drug application with the FDA to begin human clinical trials with funds it receives from its next round of financing.

About Applied Integrin Sciences

Applied Integrin Sciences is a pre-clinical stage biopharmaceutical company committed to discover, develop, and commercialize novel drug therapies and treatments for cancer that reduce tumor growth and progression and improve patient survival and quality of life.  The Company's Founding Scientists discovered, developed and patented a drug discovery platform to produce novel integrin-modulating recombinant protein drugs that reduce tumor growth and progression in primary tumors, newly growing vasculature, and metastatic foci. The company recruited an outstanding team of exceptional industry-experienced drug development and business executives to lead the company and its drug development program. The company is evaluating a novel treatment for ovarian cancer, an orphan indication recently funded by the National Cancer Institute, as its first indication. For additional information about the company, please visit www.integrins.com.

Source: Applied Integrin Sciences, Inc.

Olmstead Williams Communications, Inc.

(310) 824-9000

www.olmsteadwilliams.com

Media Contact: Public Relations, Applied Integrin Sciences, Inc., (805) 715-4166, info@integrins.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Applied Integrin Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. iBioLaunchâ„¢ Technology Successfully Applied to Modified C1 Inhibitor
2. GeneThera, Inc. Acquires Applied Genetics, S.A.
3. Thomas Elsaesser and Horst Weller receive the Julius Springer Prize for Applied Physics 2012
4. Applied Genetics Initiates Commercial Operation
5. Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology for Proteomic Applications in Research, Applied and Clinical Markets
6. Three Hertz Foundation Fellows Receive Presidential Honors; Leaders in Applied Physical, Biological and Engineering Sciences
7. USC Center For Applied Molecular Medicine To Honor Sumner Redstone And Murray Gell-Mann, Ph.D. At The Inaugural REBELS WITH A CAUSE Gala
8. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
9. APPLIED PHYSIOLOGY® Receives key US Patent Award for its Unique NAVIGATORâ„¢ Technology
10. SPIE Encouraged By Increased Science Funding in Obama Budget, Urges Applied Research Emphasis
11. SPIE Appoints Ni-Bin Chang Editor of Journal of Applied Remote Sensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, ... Actuator with a flexure design that ensures high alignment accuracy by preventing unwanted ... is ideally suited where extreme precision is required, such as in medical equipment, ...
(Date:11/30/2016)... New York , November 30, 2016 ... consolidated as a few players hold a dominant share ... Group, Charles River Laboratories International, Inc., and Merck KGaA, ... market in 2015. Transparency Market Research observes that these ... are focused on development products that are do not ...
(Date:11/30/2016)... 2016 Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... . The 15,200 square foot state-of-the-art facility officially opened ... brings the total number of BPC,s plasma collection centers ... BPC,s Chief Executive Officer said "We are pleased to ...
Breaking Biology Technology:
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):